NCT04657575 is a NA clinical trial of Narcotrend in Major Depressive Disorder, sponsored by Medical University Innsbruck.

Who is sponsoring NCT04657575?

NCT04657575 is sponsored by Medical University Innsbruck.

What drugs are being tested in NCT04657575?

Interventions in NCT04657575: Narcotrend.

What condition does NCT04657575 study?

NCT04657575 studies Major Depressive Disorder.

Is NCT04657575 still recruiting?

NCT04657575 is currently completed. Last updated 3 November 2023.

Last reviewed 2023-11-03 · How we verify

NCT04657575

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimisation of ECT Based on ASTI vs Narcotrend

Completed NA Last updated 3 November 2023

What this trial tests

NA trial testing Narcotrend in Major Depressive Disorder in 31 participants. Completed in 28 February 2023.

Timeline

1 March 2021

Primary endpoint
28 February 2023

28 February 2023

Quick facts

Lead sponsor	Medical University Innsbruck
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	basic science
Enrollment	31
Start date	1 March 2021
Primary completion	28 February 2023
Estimated completion	28 February 2023
Sites	1 location across Austria

Drugs / interventions tested

Narcotrend

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Medical University Innsbruck

Who can join

Adults 18 to 90, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Electro-Convulsion-Therapy (ECT) is a well accepted treatment option in severe depression. The quality of ECT is evaluated basing on minimal seizure duration (\>15sec), the sympathic response and the postictal EEG-suppression. \- Page 1 of 3 - For the treatment general anaesthesia is needed. On the other hand anaesthesia strongly influences the quality of the seizure. Standard treatment is to use Anaesthesia to intervention time (ASTI) of 1 to 2 minutes for ideal timing of the electric stimulation. The aim of the study is to assess if timing of electric stimulation aiming for ar an anaesthesia depth of Narcotrend values 41-64 may provide better convulsion quality than standard approach of using ASTI 1-2 minutes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Medical University Innsbruck trials

Trials by the same sponsor.

NCT07408726 — Monoaxial vs. Polyaxial Percutaneous Hybrid Stabilization · NA · not yet recruiting
NCT07101107 — Socio-cognitive and Biological Responses to Maltreatment · not yet recruiting
NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07434648 — Comparison of Mastectomy Expander Trial · NA · not yet recruiting
NCT07391683 — Telemedically Assisted Optimization for Heart Failure Patients Before Cardiac Surgery to Improve Perioperative Outcome · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04657575 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University Innsbruck
Last refreshed: 3 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04657575.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing